Michel Sadelain

Michel Sadelain is the founding director of the Center for Cell Engineering and head of the Gene Transfer and Gene Expression Laboratory at Memorial Sloan Kettering Cancer Center, where he holds the Stephen and Barbara Friedman Chair. He is also a member of the departments of medicine and pediatrics at Memorial Hospital and the molecular pharmacology and chemistry program of the Sloan Kettering Institute. Sadelain has made major contributions to the generation and optimization of CAR T cells to treat cancer, as well as the development of stem cell therapies for blood disorders. His work has focused on developing novel strategies to extend the survival of CAR T cells in the body and enable T cells with increased potency to overcome the resistance imposed by tumor and other cells in the tumor microenvironment.

Sadelain has authored more than 150 scientific papers and book chapters and received the William B. Coley Award for Distinguished Research in Tumor Immunology. He is a member of the American Society of Hematology, the American Society of Human Genetics, and the American Society of Cell and Gene Therapy, where he previously served on the board of directors and is an elected member of the American Society for Clinical Investigation. Sadelain received his MD from the University of Paris, France and his PhD from the University of Alberta, Canada.